Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis

Mingzhao Xing, Yutaka Tokumaru, Guojun Wu, William B. Westra, Paul W. Ladenson, David Sidransky

Research output: Contribution to journalArticlepeer-review

Abstract

Expression of the recently cloned Pendred syndrome gene SLC26A4 or PDS has been found to be decreased or even absent in various thyroid tumors. To explore the underlying mechanism, we conducted DNA sequencing and methylation-specific PCR studies in 64 primary thyroid tumors and 6 thyroid cell lines. We found aberrant hypermethylation of the SLC26A4 gene in 44% of histologically benign adenomas, 46% of follicular thyroid cancers, 71% of papillary thyroid cancers, 71% of anaplastic thyroid cancers, and 100% of cell lines. A reciprocal relationship between methylation and expression of the gene was confirmed in cell lines and thyroid tissues. We have thus demonstrated epigenetic changes as a new mechanism in altering the SLC26A4 gene function, in addition to genetic mutation in Pendred syndrome. SLC26A4 gene methylation in benign adenomas and the relatively well-differentiated WRO cell line suggest that this alteration is an early event in thyroid tumorigenesis.

Original languageEnglish (US)
Pages (from-to)2312-2315
Number of pages4
JournalCancer Research
Volume63
Issue number9
StatePublished - May 1 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis'. Together they form a unique fingerprint.

Cite this